Page last updated: 2024-10-30

lamotrigine and Huntington Disease

lamotrigine has been researched along with Huntington Disease in 6 studies

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy of lamotrigine, a novel antiepileptic drug that inhibits glutamate release, to retard disease progression in Huntington disease (HD)."9.09Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. ( Almqvist, EW; Clark, CM; Graf, P; Hardy, MA; Hayden, MR; Jacova, C; Kremer, B; Martin, W; Mezei, M; Raymond, LA; Snow, B, 1999)
"To assess the efficacy of lamotrigine, a novel antiepileptic drug that inhibits glutamate release, to retard disease progression in Huntington disease (HD)."5.09Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. ( Almqvist, EW; Clark, CM; Graf, P; Hardy, MA; Hayden, MR; Jacova, C; Kremer, B; Martin, W; Mezei, M; Raymond, LA; Snow, B, 1999)
"The neurodegenerative disorders (Parkinson's disease, Alzheimer's dementia, Huntington's disease, cerebellar degeneration) are common medical and social problems."2.40[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities]. ( Klivényi, P; Vécsei, L, 1997)
"Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals."1.38Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kumar, P1
Kalonia, H1
Kumar, A1
Wu, J1
Tang, T1
Bezprozvanny, I1
Shen, YC1
Martin, WR1
Hoskinson, M1
Kremer, B2
Maguire, C1
McEwan, A1
Klivényi, P1
Vécsei, L1
Clark, CM1
Almqvist, EW1
Raymond, LA1
Graf, P1
Jacova, C1
Mezei, M1
Hardy, MA1
Snow, B1
Martin, W1
Hayden, MR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

Reviews

1 review available for lamotrigine and Huntington Disease

ArticleYear
[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
    Orvosi hetilap, 1997, Feb-09, Volume: 138, Issue:6

    Topics: Aged; Aging; Alzheimer Disease; Calcium Channel Blockers; Cerebellar Diseases; Dementia; Electron Tr

1997

Trials

2 trials available for lamotrigine and Huntington Disease

ArticleYear
Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 1995, Volume: 5, Issue:4

    Topics: Anticonvulsants; Case-Control Studies; Caudate Nucleus; Deoxyglucose; Double-Blind Method; Female; F

1995
Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.
    Neurology, 1999, Sep-22, Volume: 53, Issue:5

    Topics: Adult; Anticonvulsants; Brain; Double-Blind Method; Female; Humans; Huntington Disease; Lamotrigine;

1999

Other Studies

3 other studies available for lamotrigine and Huntington Disease

ArticleYear
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
    European journal of pharmacology, 2012, Jan-15, Volume: 674, Issue:2-3

    Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap

2012
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
    Neuroscience letters, 2006, Oct-30, Volume: 407, Issue:3

    Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta

2006
Lamotrigine in motor and mood symptoms of Huntington's disease.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:2

    Topics: Antimanic Agents; Atrophy; Caudate Nucleus; Cerebral Cortex; Chorea; Female; Humans; Huntington Dise

2008